Method and composition for treating cachexia and eating disorders

• US 10,596,159 B2
• Filed: 08/11/2016
• Issued: 03/24/2020
• Est. Priority Date: 08/12/2015
• Status: Active Grant

• Current Assignee: India Globalization Capital, Inc.
• Original Assignee: India Globalization Capital, Inc.
• Inventors: Mukunda, Ramachandra, Krishna, Ranga Chelva
• Primary Examiner(s): Ward, Paul V
• Application Number:
  US15/751,901
• Publication Number:
  US 20180228788A1
• Time in Patent Office: 1,321 Days
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 31/4418 having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 36/185 Magnoliopsida (dicotyledons)
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides treating cachexia and eating disorders in humans and veterinary animals by administering a composition including: (i) cyproheptadine (CYP); and (ii) a cannabis compound selected from the group of cannabidiol (CBD) and mixtures of CBD and up to 50% tetrahydrocannabinol (THC).

Claims

1. A method for treating cachexia and eating disorders in humans and veterinary animals comprising administering to a patient in need thereof a composition comprising:

(i) cyproheptadine (CYP), wherein the CYP has a maximum dosage of about 0.2 mg/day for each kg of the patient body weight; and

(ii) a cannabis compound selected from the group of cannabidiol (CBD) and mixtures of CBD and up to 50% tetrahydrocannabinol (THC).

2. The method of claim 1 wherein the cannabis compound is phytocannabinoids.

3. The method of claim 1 wherein CBD is synthetic CBD.

4. The method of claim 1 wherein THC is synthetic THC.

5. The method of claim 2 wherein the phytocannabinoids are compounded using heated gas or supercritical or subcritical CO2.

6. The method of claim 2 wherein the phytocannabinoids are derived from Cannabis sativa, indica, or hemp.

7. The method of claim 2 wherein CBD also contains minor or trace amounts of cannabinol (CBN), cannabichromene (CBC), cannabigerol (CBG), terpenoids, flavonoids, and other material found in Cannabis plants.

8. The method of claim 1 wherein the dosage of cannabis compound is from about 10 to about 300 mg/day.

9. The method of claim 1 wherein the dosage of CYP to cannabis compound is in the ratio of about 1:

50 up to about 1;

1500.

10. A composition comprising:

(i) cyproheptadine (CYP), wherein the CYP has a maximum dosage of about 0.2 mg/day for each kg of the patient body weight; and

(ii) a cannabis compound selected from the group of cannabidiol (CBD) and mixtures of CBD and up to 50% tetrahydrocannabinol (THC).

11. The composition of claim 10 wherein the cannabis compound is phytocannabinoids.

12. The composition of claim 10 wherein CBD is synthetic CBD.

13. The composition of claim 10 wherein THC is synthetic THC.

14. The composition of claim 11 wherein the phytocannabinoids are compounded using heated gas or supercritical or subcritical CO2.

15. The composition of claim 11 wherein the phytocannabinoids are derived from Cannabis sativa, indica, or hemp.

16. The composition of claim 11 wherein CBD also contains minor or trace amounts of cannabinol (CBN), cannabichromene (CBC), cannabigerol (CBG), terpenoids, flavonoids and other material found in Cannabis plants.

17. The composition of claim 10 wherein the amount of cannabis compound present is from about 10 to about 300 mg/day.

18. The composition of claim 10 wherein the ratio of CYP to cannabis compound is about 1:

50 up to about 1;

1500.